Glyclopyramide
![]() | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
631-27-6 |
| PubChem (CID) | 71793 |
| ChemSpider |
64820 |
| UNII |
KE474IKG1W |
| KEGG |
D01799 |
| ChEMBL |
CHEMBL2105083 |
| Chemical and physical data | |
| Formula | C11H14ClN3O3S |
| Molar mass | 303.76 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Glyclopyramide (INN, marketed under the tradename Deamelin-S) is a sulfonylurea drug used in the treatment of diabetes. It has been marketed in Japan since 1965.
It is classified as second generation.[1]
References
- ↑ Ozawa H, Murai Y, Ozawa T (2003). "[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]". Yakugaku Zasshi (in Japanese). 38 (1): 11–27. PMID 14570054.
External links
This article is issued from Wikipedia - version of the 8/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
